Compare Avient Corporation (AVNT) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avient Corporation vs Merck & Co., Inc. — how do they compare? Avient Corporation trades at $35.82 (market cap $3.28B), while Merck & Co., Inc. trades at $123.25 (market cap $298.31B). The key difference: Merck & Co., Inc. is far larger — about 90.9× Avient Corporation's market cap, and Avient Corporation pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| AVNT | MRK | |
|---|---|---|
Market Cap | $3.28B | $298.31B |
Sector | Technology | Health |
52-Week High | $43.28 | $129.52 |
52-Week Low | $27.48 | $77.60 |
Enterprise Value | $4.78B | $341.72B |
Dividend Yield | 3.07% | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Avient Corporation (AVNT) trades at $35.57, down 1.28% with a bearish technical signal. The company shows consistent earnings beats with Q1 2026 EPS of $0.83 exceeding expectations. Fundamentals reveal a P/E of 20.79 and net income margin of 4.81%, while cash flow trends improved from -$34M in 2025 to -$28M projected for 2026. Recent developments include new product launches and ClassNK approval for Dyneema DM20 fiber, supporting growth in renewable energy markets.
AVNT presents a mixed outlook with strong analyst support (60% buy ratings) offset by near-term technical weakness. The company's innovation pipeline and cost control measures provide upside potential, though macroeconomic headwinds and competitive pressures remain key risks. Earnings growth and successful market expansion of new technologies are critical catalysts for stock performance.
Merck (MRK) trades at $124.03, up 0.4% on the day, with a bullish technical signal and strong analyst support. The company reported solid earnings beats in recent quarters, including Q1 2026's better-than-expected loss, and maintains robust profitability with a net income margin of 13.59%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth efforts amid competitive pressures.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include patent expirations and rising debt. With a consensus price target of $137.30 offering ~11% upside, the stock presents a compelling opportunity for growth-oriented investors, though macroeconomic and regulatory headwinds warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Avient Corporation
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
